Fas Inhibitor ONL1204 Reduces Geographic Atrophy Lesion Growth in Phase 1b Trial
Overview
In a phase 1b study, the investigational Fas inhibitor ONL1204 demonstrated significant reductions in geographic atrophy (GA) lesion growth, with up to 50% reduction after two injections. The treatment was well tolerated with minimal adverse events and showed promising neuroprotective effects in patients with GA secondary to AMD.
Background
Geographic atrophy (GA) is a progressive retinal disease characterized by photoreceptor cell death and retinal pigment epithelium (RPE) degeneration, leading to vision loss. Fas receptors play a key role in apoptosis signaling, and their activation contributes to photoreceptor death and retinal inflammation. ONL1204 is a 12 amino acid peptide designed to inhibit Fas activation, aiming to preserve photoreceptors and provide neuroprotection. Prior preclinical models demonstrated its potential, prompting clinical evaluation in GA patients.
Data Highlights
| Study Arm | Intervention | Lesion Growth Reduction at 6 Months |
|---|---|---|
| Dose-Escalation | Single ONL1204 Injection | 42% vs untreated fellow eye |
| Randomized Low-Dose | 2 ONL1204 Injections (50 µg) | 24% vs sham |
| Randomized High-Dose | 2 ONL1204 Injections (200 µg) | 50% vs sham |
Key Findings
- ONL1204 was safe and well tolerated with minimal adverse events, including one transient intraocular pressure increase and one mild vitreous floater.
- A single intravitreal injection of ONL1204 led to a 42% reduction in GA lesion growth compared to the untreated fellow eye at 6 months.
- Two injections spaced 3 months apart resulted in a 24% lesion growth reduction at low dose and a 50% reduction at high dose compared to sham treatment.
- Exploratory AI analyses showed less ellipsoid zone attenuation and reduced retinal pigment epithelium area at risk in ONL1204-treated eyes versus sham.
- ONL1204-treated eyes exhibited increased retinal thickness near lesions over time, suggesting structural preservation.
- The neuroprotective mechanism of Fas inhibition may have broader applications in other retinal diseases characterized by cell death and neurodegeneration.
Clinical Implications
ONL1204 offers a promising new therapeutic approach for GA by significantly slowing lesion progression with a favorable safety profile. Its neuroprotective effects suggest potential utility in other retinal conditions involving apoptosis and neurodegeneration. Clinicians should anticipate further data from ongoing phase 2 trials to better define its role in clinical practice.
Conclusion
The phase 1b trial results indicate that Fas inhibition with ONL1204 is a safe and effective strategy to reduce GA lesion growth, supporting further development of this novel neuroprotective agent in retinal degenerative diseases.
References
- Borkar D, Retina World Congress 2025 -- Fas Inhibition Shows Neuroprotective Benefit for Geographic Atrophy
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.